{"id":"9f56df8b6471","type":"article","url":"https://hartvaat.nl/2016/06/01/chronische-nebivololbehandeling-onderdrukt-endotheline-1-gemedieerde-vasoconstri/","title":"Chronische nebivololbehandeling onderdrukt endotheline-1-gemedieerde vasoconstrictie bij verhoogde bloeddruk","title_en":"Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["anemie-ckd","aprocitentan","bloeddrukbehandeling","chronische-nierziekte","diuretica","dubbele-trombocytenremming","endotheel","endothelineantagonisten","nt-probnp","rosuvastatine","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.115.06979","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.115.06979","authors":["Kyle J Diehl","Brian L Stauffer","Caitlin A Dow","Tyler D Bammert","Danielle L Brunjes","Jared J Greiner","Christopher A DeSouza"],"significance":5,"published":"2016-06-01","source_date":"2016-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This study showed that chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstriction in adults with elevated blood pressure, characterizing a vasodilatory mechanism specific to this third-generation beta-blocker.","created":"2026-07-03T10:26:09Z","updated":"2026-07-03T18:38:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie die aantoont dat chronische nebivololbehandeling de endotheline-1-gemedieerde vasoconstrictortonus onderdrukt bij volwassenen met verhoogde bloeddruk. Mechanistisch inzicht in de vasodilaterende eigenschappen van nebivolol.","abstract_original":"UNLABELLED: Endothelin-1 (ET-1) plays a major role in the pathophysiology of hypertension and its associated cardiovascular risk. We tested the hypothesis that chronic nebivolol treatment reduces ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure (BP). Furthermore, reducing ET-1 vasoconstrictor activity contributes to the improvement in endothelial vasodilator function associated with nebivolol treatment. Forty-two middle-aged adults with elevated BP (systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg) completed a 3-month, double-blind, randomized, placebo controlled trial: 14 received nebivolol (8 men/6 women; 5 mg per day); 14 received metoprolol succinate (9 men/5 women; 100 mg per day); and 14 received placebo (9 men/5 women). Forearm blood flow (plethysmography) responses to selective (BQ-123: 100 nmol/min; 60 minutes) and nonselective (BQ-123+BQ-788 [50 nmol/min]; 60 minutes) ET-1 receptor blockade, as well as acetylcholine (4.0, 8.0, and 16.0 μg per 100 mL of tissue per minute) in the absence and presence of nonselective ET-1 receptor blockade were determined before and after each treatment intervention. Forearm blood flow responses to BQ-123 and BQ-123+BQ-788 were similarly and significantly elevated (≈30% and 60%, respectively) from baseline in all 3 groups. Nebivolol, but not metoprolol or placebo, therapy resulted in a marked (≈25% and 45%; P<0.05) reduction in forearm blood flow response to BQ-123 and BQ-123+BQ-788. Moreover, after nebivolol therapy only, vasodilator response to acetylcholine was not significantly increased by ET-1 receptor blockade. These results demonstrate that nebivolol, but not metoprolol, treatment reduces ET-1-mediated vasoconstrictor tone in adult humans with elevated BP. In addition, nebivolol-induced reduction in ET-1-mediated vasoconstrictor tone underlies the favorable effects of this β-blocker on endothelial vasodilation. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01395329."}